Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | FADS1 | O60427 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802031 | 0.89 | GSK3A (0.45) | EGFRFADS1EPHA4CYP1A2CYP3A4 | |
| SCHEMBL801681 | 0.88 | FADS1 (0.43) | EGFRFADS1ADRA2ATRPA1GRM4 | |
| SCHEMBL805597 | 0.85 | ACP1 (0.39) | EGFRFADS1ADRA2ATRPA1GRM4 | |
| SCHEMBL802329 | 0.82 | VCP (0.38) | EGFRFADS1ADRA2ATRPA1GRM4 | |
| SCHEMBL802674 | 0.82 | GSK3A (0.44) | EGFRFADS1ADRA2ATRPA1GRM4 | |
| SCHEMBL13055198 | 0.79 | FADS1 (0.37) | EGFRFADS1ADRA2ATRPA1GRM4 | |
| SCHEMBL801676 | 0.78 | FADS1 (0.46) | EGFRFADS1EPHA4 | |
| SCHEMBL801648 | 0.77 | SYK (0.44) | FADS1ADRA2ATRPA1GRM4PIK3CD | |
| SCHEMBL14437379 | 0.77 | EGFR (0.33) | EGFRFADS1ADRA2ATRPA1GRM4 | |
| SCHEMBL10267479 | 0.76 | ACP1 (0.40) | EGFRFADS1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | EGFR 154/4885FADS1 3442/4885ADRA2A 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.